CAMBRIDGE, MA – October 7, 2024 – HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company today announced its participation in the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 6-10 in Houston, Texas.
The company will present a pioneering clinical development strategy, showcasing the predictive power of its Drug Intelligence Science (DIS®) platform to guide the Phase I development of two novel monoclonal antibodies: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069). DIS® provides a single cell and AI/ML-driven approach to selecting the most promising tumor types, dose regimen, and patient population for clinical success.
HiFiBiO’s unique DIS® approach enables the translation of complex clinical data including patient history, imaging, PK/PD, and genomic sequencing into meaningful patient selection strategies for enhanced clinical benefit. This patient-data guided translational strategy demonstrates the company’s deep commitment to innovative research and impactful therapies to address the highest unmet medical needs.
Details on the poster presentations are as follows:
Title: Predictive and Generative AI to guide the clinical development of HFB200301, a first-in-class TNFR2 agonist: Drug Intelligence Science (DIS®).
Abstract Number: 1233
Session Date: Friday, 8 November 2024
Speaker: Spencer Huggett, PhD, HiFiBiO Inc.
Title: Utilizing Drug Intelligence Science (DIS®) for tumor type selection and molecular characterization of HFB200603, a best-in-class B and T Lymphocyte Attenuator (BTLA) monoclonal antagonist.
Abstract Number: 1224
Session Date: Saturday, 9 November 2024
Speaker: Spencer Huggett, PhD, HiFiBiO Inc.
The initial data from these abstracts will be available on the SITC website starting on November 5 at 9 am EST. Additionally, the posters will be accessible on the HiFiBiO Therapeutics website following the live presentation.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage biotech driving a robust clinical pipeline of transformative immunotherapies targeting cancer and autoimmune diseases. HiFiBiO achieves an unprecedented understanding of immune modulation in human diseases by pioneering a unique high-resolution translational platform, Drug Intelligence Science (DIS®), which combines unique single-cell capabilities with AI/ML approaches. Using patient samples, DIS® enables the discovery of novel targets, effective antibody drugs, and predictive biomarkers to enhance the probability of success for immunotherapies. Moreover, HiFiBiO has established partnerships with major multinational pharmaceutical and biotech companies and has been recognized as one of the 2023 Fierce 15 biotech companies. For additional information, please visit www.hifibio.com
HiFiBiO® is a trademark of HiFiBiO Therapeutics and its affiliates